TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22193342

Group type: EXPERIMENTAL
Intervention: 6 × 10 protocol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Speedo Resistance Equipment (W situation)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No Speedo Resistance Equipment (WO situation)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Post-exercise analysis with Speedo Resistance Equipment (W situation)
Number of subjects: 10
Study: 21056314

Group type: EXPERIMENTAL
Intervention: Microdose GnRH agonist flare (MF)
Number of subjects: 94

Group type: COMPARATOR
Intervention: GnRH antagonist/letrozole
Number of subjects: 94
Study: 17432075

Group type: EXPERIMENTAL
Intervention: DARS-group (1 MAC desflurane; remifentanil: 0.2 microg x kg(‐1) x min(‐1))
Number of subjects: 100

Group type: COMPARATOR
Intervention: RADS-group (desflurane: 0.5 MAC; remifentanil: 0.4 microg x kg(‐1) x min(‐1))
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DARS-group
Number of subjects: 100

Group type: COMPARATOR
Intervention: RADS-group
Number of subjects: 100
Study: 15910732

Group type: EXPERIMENTAL
Intervention: Post-call surgeons (32)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Post-work surgeons (32)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Surgeons (64)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nurses (64)
Number of subjects: 64
Study: 12042457

Group type: EXPERIMENTAL
Intervention: 750 microg of folate
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: 15 microg of vitamin B-12
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: 75 mg of vitamin B-6
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 9504355

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7999930

Group type: EXPERIMENTAL
Intervention: Carbohydrate meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protein meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noncaloric placebo meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fasting condition
Number of subjects: 0
Study: 3142984

Group type: EXPERIMENTAL
Intervention: Parenteral lipid infusion (IL) (Vitrum)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No parenteral lipid infusion (NL)
Number of subjects: 42
Study: 30139562

Group type: EXPERIMENTAL
Intervention: MEND2-5
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: MEND/CATCH6-12
Number of subjects: 549

Group type: COMPARATOR
Intervention: Next Steps
Number of subjects: 549
Study: 29037632

Group type: EXPERIMENTAL
Intervention: Superficial dry needling
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Deep dry needling
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30
Study: 26479162

Group type: EXPERIMENTAL
Intervention: Oxycodone/Acetaminophen (5 mg/325 mg)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Hydrocodone/Acetaminophen (5 mg/325 mg)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 220
Study: 24521629

Group type: EXPERIMENTAL
Intervention: Niacin 750 mg/day
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Niacin 1500 mg/day
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Fenofibrate 160 mg/day
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Fenofibrate 320 mg/day
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Niacin
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 200
Study: 22704426

Group type: EXPERIMENTAL
Intervention: MIP (mitomycin-ifosfamide-cisplatin)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: GVP (gemcitabine-vinorelbine-cisplatin)
Number of subjects: 140
Study: 19162468

Group type: EXPERIMENTAL
Intervention: Phenylephrine (40-120 microg, administered as intermittent i.v. bolus)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Phenylephrine (intermittent boluses)
Number of subjects: 50
Study: 17204681

Group type: EXPERIMENTAL
Intervention: Anticoagulants (unfractionated heparin or low‐molecular‐weight heparin or heparinoids)
Number of subjects: 4624
Study: 15015607

Group type: EXPERIMENTAL
Intervention: Endoscopic stenting
Number of subjects: 18

Group type: COMPARATOR
Intervention: Surgery (Gastroenterostomy)
Number of subjects: 18
Study: 11257244

Group type: EXPERIMENTAL
Intervention: Alcohol (0.4 g/kg p.o., approximately 2‐3 standard drinks)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Controlled alcohol intake (0.8 g/kg/day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo conditions
Number of subjects: 9
Study: 9444594

Group type: EXPERIMENTAL
Intervention: LD-PDGF/IGF-I (50 micrograms/ml each of rhPDGF-BB and rhIGF-I in a gel vehicle)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: HD-PDGF/IGF-I (150 micrograms/ml each of rhPDGF-BB and rhIGF-I plus vehicle)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (conventional periodontal flap surgery or surgery plus vehicle)
Number of subjects: 38
Study: 7524312

Group type: EXPERIMENTAL
Intervention: Oral fluid antibody testing for hepatitis C
Number of subjects: 216
Study: 3226754

Group type: EXPERIMENTAL
Intervention: High-Dosage Regimen (HDR; n = 51) - NS 550 mg every 8 h for 3 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low-Dosage Regimen (LDR; n = 49) - Initial dose of NS 550 mg followed by NS 275 mg every 8 h through day 3
Number of subjects: 100
Study: 2192301

Group type: EXPERIMENTAL
Intervention: DGAVP citrate (Org 5667)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 4132247

Group type: EXPERIMENTAL
Intervention: FSH/LH-RH treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Unstimulated controls
Number of subjects: 16
Study: 31452420

Group type: EXPERIMENTAL
Intervention: CTHC (thermochemotherapy with pirarubicin)
Number of subjects: 300

Group type: COMPARATOR
Intervention: THP (instillation of pirarubicin without hyperthermia)
Number of subjects: 300
Study: 28103841

Group type: COMPARATOR
Intervention: Usual Nicotine Content (11.6 mg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Reduced Nicotine Content (progressively reduced from 11.6 mg to 0.2 mg)
Number of subjects: 200
Study: 26252522

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg (NMBA group)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Normal saline (No‐NMBA group)
Number of subjects: 160
Study: 23627835

Group type: EXPERIMENTAL
Intervention: Stress Management (SM) group
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 21237635

Group type: EXPERIMENTAL
Intervention: Manual and manipulative therapy (MMT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Night splint (control)
Number of subjects: 30
Study: 18783735

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 731

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 731
Study: 17302600

Group type: COMPARATOR
Intervention: EC‐MPS
Number of subjects: 246
Study: 14740329

Group type: EXPERIMENTAL
Intervention: Additional diet education (20 to 30 minutes per month)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Routine laboratory results review (control group)
Number of subjects: 63
Study: 11139557

Group type: EXPERIMENTAL
Intervention: Flexible hysteroscope
Number of subjects: 142

Group type: COMPARATOR
Intervention: Rigid hysteroscope
Number of subjects: 142
Study: 10196853

Group type: EXPERIMENTAL
Intervention: Debacterol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Kenalog-in-Orabase
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 60
Study: 7879405

Group type: EXPERIMENTAL
Intervention: Multimodal pain management
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Visualization techniques
Number of subjects: 46

Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 46

Group type: COMPARATOR
Intervention: Medical treatment alone (control)
Number of subjects: 46
Study: 3344600

Group type: EXPERIMENTAL
Intervention: Butorphanol plus diazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fentanyl plus diazepam
Number of subjects: 0
Study: 31891824

Group type: EXPERIMENTAL
Intervention: Whole-cell pertussis (wP) vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Any dose as wP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: wP-only
Number of subjects: 0

Group type: COMPARATOR
Intervention: aP vaccination
Number of subjects: 0
Study: 28699850

Group type: EXPERIMENTAL
Intervention: Balance training intervention (exercises on balance devices)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (breathing exercises and aerobic physical training, six times/week, 45 minutes)
Number of subjects: 19
Study: 27465028

Group type: EXPERIMENTAL
Intervention: 8 weeks' training in book sharing
Number of subjects: 91

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 91
Study: 23845010

Group type: EXPERIMENTAL
Intervention: Selective family‐focused violence prevention program
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Universal intervention composed of a student social‐cognitive curriculum and teacher training
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Combination of universal and selective interventions
Number of subjects: 334

Group type: COMPARATOR
Intervention: No-intervention control condition
Number of subjects: 334
Study: 21963145

Group type: EXPERIMENTAL
Intervention: 20-day balance training (group A)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Group B (without training)
Number of subjects: 26
Study: 20482894

Group type: EXPERIMENTAL
Intervention: Accelerated hand BMD loss (>‐0.003 g/cm2) in the first year of RA
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Hand BMD loss in the first year
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Progressive joint damage in the first year
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Anti-citrullinated protein antibody positivity
Number of subjects: 256
Study: 17966028

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 52

Group type: COMPARATOR
Intervention: Cast treatment
Number of subjects: 52
Study: 16210834

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) of 0.625 mg plus medroxyprogesterone acetate (MPA) of 2.5 mg (n = 79)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) of 0.625 mg plus medroxyprogesterone acetate (MPA) of 5 mg (n = 77)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Tibolone of 2.5 mg (n = 76)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Calcium (Ca) of 1,000 mg (n = 54)
Number of subjects: 286
Study: 12270249

Group type: EXPERIMENTAL
Intervention: Monodose inhaler (Miat)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pulmicort Turbuhaler DPI
Number of subjects: 12
Study: 10323625

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (1 mg/kg body weight)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 8691896

Group type: EXPERIMENTAL
Intervention: Corrective rearfoot orthotic device
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard shoe with no device
Number of subjects: 25
Study: 1908584

Group type: EXPERIMENTAL
Intervention: Ritanserin (10 mg PO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: No pill
Number of subjects: 30
Study: 6409135

Group type: EXPERIMENTAL
Intervention: Extradural anaesthesia with 0.5% bupivacaine with adrenaline continued into the postoperative period (24 h)
Number of subjects: 30

Group type: COMPARATOR
Intervention: General anaesthesia with controlled ventilation, using nitrous oxide in oxygen and fentanyl i.v.
Number of subjects: 30
Study: 29862491

Group type: EXPERIMENTAL
Intervention: 0.5% colchicine cream
Number of subjects: 36

Group type: COMPARATOR
Intervention: Methyl aminolaevulinate photodynamic therapy (MAL-PDT)
Number of subjects: 36
Study: 27228268

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Acupoint Stimulation (TEAS)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 75
Study: 24569032

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 2216

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 2216
Study: 22546733

Group type: EXPERIMENTAL
Intervention: Patient-controlled, forced-air warming gown
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard hospital gown and prewarmed standard cotton blanket
Number of subjects: 30
Study: 21203389

Group type: EXPERIMENTAL
Intervention: Standard SP‐IPTp
Number of subjects: 3333

Group type: EXPERIMENTAL
Intervention: IST and treatment with SP
Number of subjects: 3333

Group type: EXPERIMENTAL
Intervention: IST and treatment with AQ+AS
Number of subjects: 3333

Group type: COMPARATOR
Intervention: SP‐IPTp
Number of subjects: 3333
Study: 16895615

Group type: COMPARATOR
Intervention: Air and oxygen mixture through a Hudson style face mask (FiO2 of 0.21‐0.25)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FiO2 of 0.40‐0.60 through an identical Hudson style face mask
Number of subjects: 60
Study: 16307045

Group type: EXPERIMENTAL
Intervention: Enerlit‐Clima (bioactive succinate‐based food additive)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11948271

Group type: COMPARATOR
Intervention: Intravenous ganciclovir
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Oral valganciclovir
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir and Oral valganciclovir
Number of subjects: 160
Study: 10451813

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Oral 17 beta‐estradiol
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta‐estradiol
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study: 8519718

Group type: EXPERIMENTAL
Intervention: Sitting position with 3 mL lidocaine 1.5% and 12 mL bupivacaine 0.75%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supine position with 3 mL lidocaine 1.5% and 12 mL bupivacaine 0.75%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 40
Study: 2130290

Group type: EXPERIMENTAL
Intervention: 50 mg phenobarbital
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 100 mg phenobarbital
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 475546

Group type: EXPERIMENTAL
Intervention: Highly experienced psychotherapists
Number of subjects: 15

Group type: COMPARATOR
Intervention: College professors
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Treated groups
Number of subjects: 15
Study: 31647838

Group type: EXPERIMENTAL
Intervention: Virtual Sleep Unit (VSU)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Hospital Routine (HR)
Number of subjects: 186
Study: 28669962

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.25 µg/kg + 0.25% ropivacaine (0.20 mL/kg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.50 µg/kg + 0.25% ropivacaine (0.20 mL/kg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.75 µg/kg + 0.25% ropivacaine (0.20 mL/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (0.25% ropivacaine only)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study: 25772196

Group type: EXPERIMENTAL
Intervention: Omelette
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cottage Cheese
Number of subjects: 30
Study: 24159085

Group type: EXPERIMENTAL
Intervention: Gompertz function analysis
Number of subjects: 469
Study: 21205129

Group type: EXPERIMENTAL
Intervention: Pregnancy occurred
Number of subjects: 532

Group type: COMPARATOR
Intervention: No pregnancy occurred
Number of subjects: 532
Study: 19470629

Group type: EXPERIMENTAL
Intervention: IDet (2 mU/kg . min for 4 h, followed by 4 mU/kg . min for 1 h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: HI (1 mU/kg . min for 4 h, followed by 2 mU/kg . min for 1 h)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: IDet
Number of subjects: 10

Group type: COMPARATOR
Intervention: HI
Number of subjects: 10
Study: 17719702

Group type: EXPERIMENTAL
Intervention: Plant sterol-enriched products (20 g low-fat margarine and 250 ml low-fat milk delivering 2.3g plant sterols/d)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 15601557

Group type: EXPERIMENTAL
Intervention: Intratumoral H101 injection combined with PF regimen (cisplatin + 5-fluorouracil)
Number of subjects: 160

Group type: COMPARATOR
Intervention: PF regimen alone
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Intratumoral H101 injection combined with AF regimen (adriamycin + 5-fluorouracil)
Number of subjects: 160

Group type: COMPARATOR
Intervention: AF regimen alone
Number of subjects: 160
Study: 11523980

Group type: EXPERIMENTAL
Intervention: stannous fluoride dentifrice and hyG Brnde ionizing brush without a battery
Number of subjects: 32

Group type: COMPARATOR
Intervention: stannous fluoride dentifrice and hyG Brnde ionizing brush with a battery
Number of subjects: 32
Study: 9551737

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg at 30 L x min[‐1]
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg at 90 L x min[‐1]
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo at 30 L x min[‐1]
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo at 90 L x min[‐1]
Number of subjects: 18
Study: 8823352

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study: 2390155

Group type: EXPERIMENTAL
Intervention: 1% lignocaine with higher pH
Number of subjects: 20

Group type: COMPARATOR
Intervention: 1% lignocaine with standard pH
Number of subjects: 20
Study: 7020917

Group type: EXPERIMENTAL
Intervention: L-phenylalanine mustard (L-PAM)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, 5-fluorouracil, and methotrexate (CMF)
Number of subjects: 158

Group type: COMPARATOR
Intervention: R.T. plus L-PAM
Number of subjects: 158

Group type: COMPARATOR
Intervention: CMF
Number of subjects: 158

Group type: COMPARATOR
Intervention: R.T. plus CMF
Number of subjects: 158
Study: 30234669

Group type: EXPERIMENTAL
Intervention: Simulation training (Group SIM) with 60 minutes of simulation practice
Number of subjects: 0

Group type: COMPARATOR
Intervention: No simulation training (Group CON)
Number of subjects: 0
Study: 28730328

Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine patch (5, 10, 15, and 20 μg/h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral tramadol (150, 200, 250, and 300 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (Buprenorphine and Tramadol)
Number of subjects: 0
Study: 26492082

Group type: EXPERIMENTAL
Intervention: Amino acid mixture deficient in dopamine precursors (APTD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nutritionally-balanced amino acid mixture (BAL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: APTD
Number of subjects: 12

Group type: COMPARATOR
Intervention: BAL
Number of subjects: 12
Study: 24196866

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 23089349

Group type: EXPERIMENTAL
Intervention: Inflated pneumatic tourniquet (group A, n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Deflated pneumatic tourniquet (group B, n = 40)
Number of subjects: 80
Study: 19777852

Group type: EXPERIMENTAL
Intervention: Chaihu Shihuang soup once a day for 7 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dachaihu soup once daily for 7 days
Number of subjects: 60
Study: 18085153

Group type: EXPERIMENTAL
Intervention: Acup-moxibustion plus western medicine
Number of subjects: 132

Group type: COMPARATOR
Intervention: Western medication
Number of subjects: 132
Study: 15382818

Group type: EXPERIMENTAL
Intervention: Knowledge of a 2nd language
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Deceptive interaction condition
Number of subjects: 197

Group type: COMPARATOR
Intervention: Deceptive-context condition
Number of subjects: 197

Group type: COMPARATOR
Intervention: Older peer condition
Number of subjects: 197
Study: 11528347

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 19
Study: 9370106

Group type: EXPERIMENTAL
Intervention: Exogenous GLP-1 (administered i.v. or s.c.)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 1396820

Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg t.i.d.
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 4011640

Group type: EXPERIMENTAL
Intervention: 0.66 ml/kg of body weight
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1.2 ml/l of total body water
Number of subjects: 24
Study: 31325345

Group type: EXPERIMENTAL
Intervention: 17% watery solution of glycerol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxygenated glycerol triester (Aequasyal)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newly developed product (Salient)
Number of subjects: 0
Study: 29691286

Group type: COMPARATOR
Intervention: Sedentary lifestyle (compared to physically active)
Number of subjects: 10626

Group type: EXPERIMENTAL
Intervention: Increasing age and dementia
Number of subjects: 10626

Group type: EXPERIMENTAL
Intervention: Depression and alcohol consumption
Number of subjects: 10626

Group type: EXPERIMENTAL
Intervention: Poor physical function, physical inactivity, and smoking
Number of subjects: 10626

Group type: EXPERIMENTAL
Intervention: Gender-specific models
Number of subjects: 10626
Study: 26778329

Group type: EXPERIMENTAL
Intervention: Ranibizumab or Bevacizumab treatment for CME
Number of subjects: 1131
Study: 25439038

Group type: EXPERIMENTAL
Intervention: Individualized homeopathy
Number of subjects: 162

Group type: COMPARATOR
Intervention: Identical placebo (control)
Number of subjects: 162
Study: 22380577

Group type: EXPERIMENTAL
Intervention: Bisphosphonates (weekly alendronate/risedronate)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Patient counselling
Number of subjects: 198